Trial reportThe Journal of clinical investigation2020
A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome.
Trial report in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 186 citations in OpenAlex.
- Bibliometric and visual analysis of gut microbiota research in functional bowel disorders from 2016 to 2025.Frontiers in medicine · 2026Pooled it
- Effectiveness of diet, psychological, and exercise therapies for the management of bile acid diarrhoea in adults: A systematic review.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2022Pooled it
- Re-establishing bile acid composition after treatment of recurrentGut microbes · 2026Trial
- Changing Gastrointestinal Transit Time Alters Microbiome Composition and Bile Acid Metabolism: A Cross-Over Study in Healthy Volunteers.Neurogastroenterology and motility · 2025Trial
- Defecation status, intestinal microbiota, and habitual diet are associated with the fecal bile acid composition: a cross-sectional study in community-dwelling young participants.European journal of nutrition · 2023Trial
- Bile acid signaling in health and disease.Molecular biomedicine · 2026Review
- Irritable bowel syndrome.Nature reviews. Disease primers · 2026Review
- Gut microbiota-bile acid axis in cardiovascular disease: a spatiotemporal framework for predictive, preventive and personalised medicine.The EPMA journal · 2026Review
- Dietary sublancin or oregano essential oil enhances growth and immunity in goat kids via modulating colonic microbiota and bile acids.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- Gut Microbiota-Isoallolithocholic Acid Crosstalk Promotes Calcium Oxalate Kidney Stone Formation via PARP1-Mediated Parthanatos.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Shenling Baizhu Powder Modulates Gut Microbiota and Bile Acid Signaling to Alleviate Diet-Induced Diarrhea.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Dynamic effects of radioactive iodine therapy on gut microbiota and metabolites in patients with papillary thyroid cancer.Microbiology spectrum · 2026Article
- Obesogenic Diets Composition Differentially Alters theNutrients · 2026Article
- GV-971 remodels the gut microbiota-bile acid-FXR axis to ameliorate obesity and metabolic dysfunction.Cell discovery · 2026Article
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Parabacteroides goldsteinii-derived outer membrane vesicles alleviate acute lung injury via modulation of bile acid metabolism.Journal of nanobiotechnology · 2026Article
- Clinical efficacy of Xifeng Huashi and its effect on mental status in patients with diarrheal irritable bowel.World journal of psychiatry · 2026Article
- Genomic insights into the functional and metabolic versatility of gut microbiomeMicrobial genomics · 2026Article
- Article
- Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea.Journal of inflammation research · 2026Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An excess of fecal bile acids (BAs) is thought to be one of the mechanisms for diarrhea-predominant irritable bowel syndrome (IBS-D). However, the factors causing excessive BA excretion remain incompletely studied. Given the importance of gut microbiota in BA metabolism, we hypothesized that gut dysbiosis might contribute to excessive BA excretion in IBS-D. By performing BA-related metabolic and metagenomic analyses in 290 IBS-D patients and 89 healthy volunteers, we found that 24.5% of IBS-D patients exhibited excessive excretion of total BAs and alteration of BA-transforming bacteria in feces. Notably, the increase in Clostridia bacteria (e.g., C. scindens) was positively associated with the levels of fecal BAs and serum 7α-hydroxy-4-cholesten-3-one (C4), but negatively correlated with serum fibroblast growth factor 19 (FGF19) concentration. Furthermore, colonization with Clostridia-rich IBS-D fecal microbiota or C. scindens individually enhanced serum C4 and hepatic conjugated BAs but reduced ileal FGF19 expression in mice. Inhibition of Clostridium species with vancomycin yielded opposite results. Clostridia-derived BAs suppressed the intestinal FGF19 expression in vitro and in vivo. In conclusion, this study demonstrates that the Clostridia-rich microbiota contributes to excessive BA excretion in IBS-D patients, which provides a mechanistic hypothesis with testable clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.